Non-bacterial thrombotic endocarditis overview: Difference between revisions
Aisha Adigun (talk | contribs) |
Aisha Adigun (talk | contribs) No edit summary |
||
| Line 13: | Line 13: | ||
Although the exact [[pathogenesis]] of [[non-bacterial thrombotic endocarditis]] is not completely understood, [[Endothelial dysfunction|endothelial injury]] correlated with a [[hypercoagulable state]] has been implicated. Pathogenesis can be sub-sectioned into four factors thought to be involved in instigating NBTE. These include; [[Immune complexes]][[Hypoxia|, Hypoxia]] , [[Hypercoagulability]], and[[Carcinomatosis]]. Conditions associated with nonbacterial thrombotic endocarditis include; [[Malignancies]], [[Systemic autoimmune diseases]] ([[Systemic lupus erythematosus|SLE]] is the most common,[[Hypercoagulable states]], Chronic inflammatory states, [[Heart failure]] with [[Valve dysfunction|valvulopathy]], e.t.c. | Although the exact [[pathogenesis]] of [[non-bacterial thrombotic endocarditis]] is not completely understood, [[Endothelial dysfunction|endothelial injury]] correlated with a [[hypercoagulable state]] has been implicated. Pathogenesis can be sub-sectioned into four factors thought to be involved in instigating NBTE. These include; [[Immune complexes]][[Hypoxia|, Hypoxia]] , [[Hypercoagulability]], and[[Carcinomatosis]]. Conditions associated with nonbacterial thrombotic endocarditis include; [[Malignancies]], [[Systemic autoimmune diseases]] ([[Systemic lupus erythematosus|SLE]] is the most common,[[Hypercoagulable states]], Chronic inflammatory states, [[Heart failure]] with [[Valve dysfunction|valvulopathy]], e.t.c. | ||
==Differentiating non-bacterial thrombotic endocarditis from other Diseases== | |||
==Differentiating | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Revision as of 21:37, 22 August 2020
|
non-bacterial thrombotic endocarditis |
|
Differentiating non-bacterial thrombotic endocarditis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Non-bacterial thrombotic endocarditis overview On the Web |
|
American Roentgen Ray Society Images of Non-bacterial thrombotic endocarditis overview |
|
Risk calculators and risk factors for Non-bacterial thrombotic endocarditis overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aisha Adigun, B.Sc., M.D.[2]
Overview
Historical Perspective
The association between thromboembotic events and malignancy was made by Armand Trousseau in the year 1865. In 1926, Dr. Benjamin Sacks and Dr. Emmanuel Libman published cases of "valvular masses" that were examined clinically and during autopsies and found to be free of all microorganisms. These masses were initially named "indeterminate endocarditis".
Classification
According to Allen and Sirota, Non-bacterial thrombotic endocarditis may be classified according to morphology into 5 subtypes.
Pathophysiology
Although the exact pathogenesis of non-bacterial thrombotic endocarditis is not completely understood, endothelial injury correlated with a hypercoagulable state has been implicated. Pathogenesis can be sub-sectioned into four factors thought to be involved in instigating NBTE. These include; Immune complexes, Hypoxia , Hypercoagulability, andCarcinomatosis. Conditions associated with nonbacterial thrombotic endocarditis include; Malignancies, Systemic autoimmune diseases (SLE is the most common,Hypercoagulable states, Chronic inflammatory states, Heart failure with valvulopathy, e.t.c.